MITOPlas_Scalable characterization of the malaria parasite mitochondrial proteome

MITOPlas_疟原虫线粒体蛋白质组的可扩展表征

基本信息

  • 批准号:
    9014806
  • 负责人:
  • 金额:
    $ 23.4万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-01-01 至 2017-12-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Our ability to effectively treat malaria is threatened by increasingly widespread resistance to the limited number of frontline antimalarial drugs available. Consequently, new strategies guiding prioritization of novel targets for drug development are critically needed. Here we propose targeting mitochondrial function as a strategy that could yield diverse solutions for treating malaria. The long-term goal is to define the mitochondrial proteome of the human malaria parasite, P. falciparum, and establish the core subset of these proteins that are essential for parasite survival. We envision that this knowledge will contribute to the development of new antimalarial drugs with novel mechanisms of action, and that circumvent existing modes of drug resistance. The objectives of the present research are to: (1) develop a pipeline for prioritizing then validating the set of nuclear- encoded protein that are trafficked to the mitochondrion; and (2) classify the essentiality of these proteins. The central hypothesis is that mitochondrial function is critical for malaria parasite survival during blood, mosquito and liver stages. Defining essential mitochondrial proteins and biological processes should provide new insights into fundamental parasite biology. Additionally, this can create opportunities for developing antimalarial drugs that simultaneously target blood, transmission, and liver stages of the parasite life cycle. Drugs with these characteristics are critical to malaria elimination efforts. To accomplish the objectives of this proposal, we will pursue two aims. In Specific Aim 1, we will use bioinformatics tools to predict mitochondrial targeting sequences (MTS) in nuclear-encoded proteins, and create prioritized lists of putative mitochondrial proteins. We will create libraries of MTS candidates fused to a fluorescent reporter protein and use high throughput and high content imaging to determine whether a candidate MTS is sufficient to mediate protein trafficking to the mitochondrion. In Specific Aim 2, we will use a newly developed functional genetics toolkit to epitope tag and conditionally regulate the expression level of endogenous proteins putatively trafficked to the mitochondrion. This will allow us to establish whether native proteins associated with a given MTS are indeed trafficked to the mitochondrion. Conditionally regulating the expression of these proteins will additionally facilitate assessment of which mitochondrial proteins are essential for parasite survival. Our approach is innovative because it integrates several complementary technologies-combinatorial reporter library synthesis and parasite line generation, high content imaging and functional genetics-to gain insight into mitochondrial biology on an unprecedented scale in P. falciparum. The proposed research is significant because it will provide definitive insights into the composition and vital components of this relatively enigmatic parasite organelle. Simultaneously, it will motivate targeted interference with mitochondrial function as a strategy for identifying life cycle stage-independent antimalarial drugs. These outcomes are expected to positively impact human health by improving the tools available for malaria treatment and eradication.
 描述(由申请人提供):我们有效治疗疟疾的能力受到对有限数量的一线抗疟药物日益普遍的耐药性的威胁。因此,迫切需要指导药物开发新靶点优先顺序的新策略。在这里,我们提出以线粒体功能为目标作为一种策略,可以为治疗疟疾提供多种解决方案。长期目标是确定人类疟疾寄生虫恶性疟原虫的线粒体蛋白质组,并建立这些蛋白质的核心子集,这些蛋白质对寄生虫的生存至关重要。我们设想,这些知识将有助于开发具有新作用机制的新抗疟药物,并绕过现有的耐药性模式。本研究的目标是:(1)开发一个管道,用于优先排序,然后验证一组被贩运到细胞核的核编码蛋白质;(2)对这些蛋白质的必要性进行分类。核心假设是线粒体功能对于疟原虫在血液、蚊子和肝脏阶段的存活至关重要。定义必要的线粒体蛋白和生物过程应该提供新的见解基本寄生虫生物学。此外,这可以为开发同时针对寄生虫生命周期的血液、传播和肝脏阶段的抗疟药物创造机会。具有这些特性的药物对于消灭疟疾的努力至关重要。为了实现这项建议的目标,我们将追求两个目标。在具体目标1中,我们将使用生物信息学工具来预测核编码蛋白质中的线粒体靶向序列(MTS),并创建假定线粒体蛋白质的优先级列表。我们将创建与荧光报告蛋白融合的MTS候选物的文库,并使用高通量和高含量成像来确定候选MTS是否足以介导蛋白质运输至靶点。在具体目标2中, 我们将使用新开发的功能遗传学工具包来标记表位,并有条件地调节运输到细胞的内源性蛋白质的表达水平。这将使我们能够确定与给定MTS相关的天然蛋白质是否确实被贩运到微卫星。调节这些蛋白质的表达将另外促进评估哪些线粒体蛋白质是寄生虫生存所必需的。我们的方法是创新的,因为它集成了几个互补的技术-组合报告库合成和寄生虫系生成,高内容成像和功能遗传学-以前所未有的规模深入了解恶性疟原虫线粒体生物学。这项拟议中的研究意义重大,因为它将为这种相对神秘的寄生虫细胞器的组成和重要成分提供明确的见解。同时,它将激励对线粒体功能的靶向干扰,作为确定生命周期阶段独立抗疟药物的策略。预计这些成果将通过改进治疗和根除疟疾的现有工具,对人类健康产生积极影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JACQUIN C NILES其他文献

JACQUIN C NILES的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JACQUIN C NILES', 18)}}的其他基金

Target-specific antimalarial compound identification using phenotypic assays
使用表型分析鉴定靶标特异性抗疟化合物
  • 批准号:
    10177856
  • 财政年份:
    2019
  • 资助金额:
    $ 23.4万
  • 项目类别:
Target-specific antimalarial compound identification using phenotypic assays
使用表型分析鉴定靶标特异性抗疟化合物
  • 批准号:
    10404548
  • 财政年份:
    2019
  • 资助金额:
    $ 23.4万
  • 项目类别:
Engineered Regulated RNA Localization and Transport in Biological Systems
生物系统中工程调控的 RNA 定位和运输
  • 批准号:
    7981032
  • 财政年份:
    2010
  • 资助金额:
    $ 23.4万
  • 项目类别:
Investigating the Cytsolic Heme Pool in P. falciparum
研究恶性疟原虫胞质血红素池
  • 批准号:
    6915712
  • 财政年份:
    2004
  • 资助金额:
    $ 23.4万
  • 项目类别:
Investigating the Cytsolic Heme Pool in P. falciparum
研究恶性疟原虫胞质血红素池
  • 批准号:
    6738645
  • 财政年份:
    2004
  • 资助金额:
    $ 23.4万
  • 项目类别:
Investigating the Cytsolic Heme Pool in P. falciparum
研究恶性疟原虫胞质血红素池
  • 批准号:
    7061345
  • 财政年份:
    2004
  • 资助金额:
    $ 23.4万
  • 项目类别:
MINORITY PREDOCTORAL FELLOWSHIP PROGRAM--NIGMS
少数族裔博士前奖学金计划
  • 批准号:
    6388297
  • 财政年份:
    2001
  • 资助金额:
    $ 23.4万
  • 项目类别:
MINORITY PREDOCTORAL FELLOWSHIP PROGRAM--NIGMS
少数族裔博士前奖学金计划
  • 批准号:
    6181602
  • 财政年份:
    2000
  • 资助金额:
    $ 23.4万
  • 项目类别:
MINORITY PREDOCTORAL FELLOWSHIP PROGRAM--NIGMS
少数族裔博士前奖学金计划
  • 批准号:
    6155140
  • 财政年份:
    1999
  • 资助金额:
    $ 23.4万
  • 项目类别:
MINORITY PREDOCTORAL FELLOWSHIP PROGRAM--NIGMS
少数族裔博士前奖学金计划
  • 批准号:
    2796792
  • 财政年份:
    1998
  • 资助金额:
    $ 23.4万
  • 项目类别:

相似海外基金

Developing inhibitors of Plasmodium Acetyl CoA Synthetase as new multistage antimalarials
开发疟原虫乙酰辅酶A合成酶抑制剂作为新型多级抗疟药
  • 批准号:
    MR/X030202/1
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
    Research Grant
Novel Dual-Stage Antimalarials: Machine learning prediction, validation and evolution
新型双阶段抗疟药:机器学习预测、验证和进化
  • 批准号:
    10742205
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
Natural Product Inspired Novel Antimalarials with Radical Cure Potential
受天然产物启发的具有根治潜力的新型抗疟药
  • 批准号:
    10635649
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
Novel Synergistic Antimalarials with Resistance Reversal Function
具有耐药逆转功能的新型协同抗疟药
  • 批准号:
    10534667
  • 财政年份:
    2022
  • 资助金额:
    $ 23.4万
  • 项目类别:
Plasmodium Protein Kinase Focused Antimalarials Discovery
疟原虫蛋白激酶聚焦抗疟药的发现
  • 批准号:
    10533634
  • 财政年份:
    2022
  • 资助金额:
    $ 23.4万
  • 项目类别:
DMPK Optimisation of B-hydroxyethylamine Antimalarials
B-羟乙胺抗疟药的 DMPK 优化
  • 批准号:
    2749037
  • 财政年份:
    2022
  • 资助金额:
    $ 23.4万
  • 项目类别:
    Studentship
Development of new lead antimalarials targeting parasite coenzyme A biosynthesis and utilisation.
开发针对寄生虫辅酶 A 生物合成和利用的新型先导抗疟药。
  • 批准号:
    468862
  • 财政年份:
    2022
  • 资助金额:
    $ 23.4万
  • 项目类别:
    Operating Grants
Repurposing antimalarials for the treatment of NTM infections
重新利用抗疟药治疗 NTM 感染
  • 批准号:
    10646331
  • 财政年份:
    2022
  • 资助金额:
    $ 23.4万
  • 项目类别:
Novel Synergistic Antimalarials with Resistance Reversal Function
具有耐药逆转功能的新型协同抗疟药
  • 批准号:
    10368441
  • 财政年份:
    2022
  • 资助金额:
    $ 23.4万
  • 项目类别:
Plasmodium Protein Kinase Focused Antimalarials Discovery
疟原虫蛋白激酶聚焦抗疟药的发现
  • 批准号:
    10663334
  • 财政年份:
    2022
  • 资助金额:
    $ 23.4万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了